NASDAQ$MIRM
Mirum Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Mirum Pharmaceuticals' Q2 2023 financial results were reported, highlighted by a revenue increase and strategic acquisitions.
Mirum Pharmaceuticals reported a total revenue of $37.5 million for Q2 2023, including $32.5 million from LIVMARLI net product sales. The company is acquiring CHENODAL and CHOLBAM to expand its leadership in pediatric hepatology. Four late-stage clinical trial data readouts are expected later this year.
- Total revenue reached $37.5 million, with LIVMARLI contributing $32.5 million in net product sales.
- Agreement to acquire CHENODAL and CHOLBAM was made, strengthening the company's position in pediatric hepatology.
- Global net sales grew 86% compared to Q2 2022.
- Mirum had cash, cash equivalents, and short-term investments of $330 million as of June 30, 2023.
Headline financials
Revenue & EPS history
Mirum Pharmaceuticals · Revenue · Quarterly
$37.5M
Revenue by segment
Mirum Pharmaceuticals · $29.1M total across 1 segment · Q1 2023
- Net Product Sales$29.1M—100.0%
Forward guidance
Mirum anticipates continued growth for LIVMARLI and expects multiple regulatory and pipeline catalysts in the second half of the year. The acquisition of CHENODAL and CHOLBAM is expected to add over $100 million in annual net sales.
Tailwinds
- Continued commercial success for LIVMARLI
- Growth in year-over-year net product sales
- LIVMARLI commercial growth in international markets
- Potential label expansion into PFIC
- Becoming a global leader in rare disease
Headwinds
- Risks and uncertainties associated with Mirum’s business in general
- Adverse macroeconomic and geopolitical development
- Uncertainties related to ongoing and planned studies for product candidates
- Potential delays in receipt and timing of planned data readouts
- Uncertain regulatory approval path for product candidates globally
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+26.4%
Q2 2022
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.2% | -11.7% | |
| Q4 2025 | -15.1% | -19.2% | -18.6% | |
| Q3 2025 | -1.4% | -1.8% | -3.5% | |
| Q1 2025 | +9.9% | +9.8% | +12.5% | |
| Q4 2024 | -7.0% | -10.5% | -9.0% | |
| Q3 2024 | +5.6% | +6.9% | +1.6% | |
| Q2 2024 | +1.8% | +14.3% | +5.0% | |
| Q1 2024 | -0.3% | -4.4% | -3.2% | |
| Q4 2023 | -3.0% | -3.1% | -15.2% | |
| Q3 2023 | +5.6% | +5.6% | +12.6% | |
| Q2 2023 | +6.1% | +2.1% | +6.1% | |
| Q1 2023 | -8.3% | -7.9% | -7.9% | |
| Q4 2022 | -1.1% | -4.7% | +5.1% | |
| Q3 2022 | -16.2% | -19.7% | -24.1% | |
| Q2 2022 | +26.4% | +18.0% | +7.4% | |
| Q1 2022 | +7.1% | -4.4% | +7.0% | |
| Q4 2021 | +3.3% | +1.5% | +29.5% | |
| Q3 2021 | +0.1% | -1.2% | -7.9% | |
| Q2 2021 | +0.5% | -4.0% | +23.0% | |
| Q1 2021 | -1.4% | -6.3% | -10.8% | |
| Q4 2020 | +6.0% | +14.3% | +10.2% | |
| Q3 2020 | +11.6% | +16.9% | +48.0% | |
| Q2 2020 | +13.0% | +15.3% | -4.3% | |
| Q1 2020 | +0.1% | +6.2% | +10.8% | |
| Q4 2019 | +8.1% | -10.5% | +25.7% | |
| Q3 2019 | -0.1% | +4.0% | +22.6% | |
| Q2 2019 | -9.0% | -10.3% | -31.5% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro